• Rhythm Pharmaceuticals recently announced that the European Commission expanded marketing authorization for IMCIVREE (setmelanotide) to treat obesity and control hunger in adults and children aged 4 and above with acquired hypothalamic obesity due to hypothalamic injury or impairment, based on Phase 3 TRANSCEND trial data showing a placebo-adjusted reduction in body mass index.
• This twin US and EU approval for acquired hypothalamic obesity meaningfully broadens IMCIVREE’s addressable patient pool in rare neuroendocrine disease across both major markets.
• We’ll now examine how the new EU authorization for acquired hypothalamic obesity reshapes Rhythm’s rare-disease focus and growth narrative.

Outshine the giants: these 18 early-stage AI stocks could fund your retirement.

Rhythm Pharmaceuticals Investment Narrative Recap

To own Rhythm Pharmaceuticals, you need to believe that IMCIVREE can build a durable rare-disease franchise around MC4R pathway disorders while the company narrows its losses. The new EU authorization for acquired hypothalamic obesity strengthens the core setmelanotide story, but does not change the fact that Rhythm is still loss making and reliant on a single commercial asset, with ongoing needs for capital and careful execution on pricing and reimbursement.

The most relevant recent update is the March 2026 FDA approval expanding IMCIVREE’s US label to acquired hypothalamic obesity, based on the same TRANSCEND data that underpins the EU decision. Together, these paired approvals in the US and EU align Rhythm’s rare neuroendocrine focus around hypothalamic obesity and related conditions, and they tighten the link between regulatory progress and the company’s key short term catalyst of translating label expansions into reimbursed, commercially meaningful launches.

Yet investors should also be aware that Rhythm’s heavy reliance on a single drug, combined with persistent net losses and possible future equity raises, means...

Rhythm Pharmaceuticals' narrative projects $873.3 million revenue and $209.1 million earnings by 2029.

Uncover how Rhythm Pharmaceuticals' forecasts yield a $137.67 fair value, a 68% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community currently see Rhythm’s fair value between US$131 and US$418 per share, underscoring how far views can spread. When you weigh those opinions against Rhythm’s continued operating losses and dependence on setmelanotide, it becomes even more important to compare several perspectives before forming your own view of the company’s prospects.

Explore 3 other fair value estimates on Rhythm Pharmaceuticals - why the stock might be worth just $131.13!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Rhythm Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Rhythm Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Rhythm Pharmaceuticals' overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.